Foghorn Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
500 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139
Mailing Address
500 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139
Phone
617-586-3100
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 10-K Annual financial report | March 11, 2026 | View on SEC |
| 3 Initial insider ownership report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
Annual Reports
10-K
March 11, 2026
- Strategic collaboration with a major pharmaceutical partner, including a $20.0 million upfront payment and potential milestones up to $500 million.
- Lead programs FHD-609 and FHD-286 successfully completed initial Phase 1 dose-escalation, showing promising early safety and clinical activity.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.